Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Heart CT Scans Support Personalized Medicine for Patients with Prehypertension



Heart CT scans measure the amount of calcium in arteries of the heart, which can be an indicator of which patients should be treated with antihypertensive medication.

Share this!

January 19, 2017 | by Sarah Hand, M.Sc.

Doctors follow a standard of care for patients with high blood pressure – or hypertension – which is characterized by systolic blood pressure over 140 millimeters of mercury. But for patients whose blood pressure is above normal but not considered to be high, the course of treatment is not as clearly defined.

Now, researchers at Johns Hopkins University have found that heart CT scans can help physicians determine whether patients who fall within a so-called “gray-zone” of blood pressure readings could benefit from medication. The study – which was published in the journal, Circulation – describes a method which could benefit the third of all US adults which are considered to have prehypertension.

Heart CT scans measure the amount of calcium in arteries of the heart, which can be an indicator of which patients should be treated with antihypertensive medication. If patients have little to no calcium accumulation, they may be able to avoid unnecessarily medicating with blood pressure drugs, depending on whether they have any other cardiovascular risk factors.

“If a healthcare provider wants to target blood pressure in a patient with traditional heart disease risk factors and above-normal blood pressure, he or she can look at coronary artery calcium to help with tiebreaker-like decisions,” said J. William McEvoy, M.B.B.Ch., M.H.S., assistant professor of medicine and member of the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins University School of Medicine. “Our study, along with others, such as SPRINT and HOPE, positions cardiac risk and coronary artery calcium as helpful ways to determine if a given patient would either benefit from more intensive blood pressure control or do just fine with a more traditional blood pressure target.”

Currently, risk factor equations are used to determine whether a patient with prehypertension should be medicated, however these tools rely on generalized findings which may not always be applicable on the personal level. Coronary artery calcium scores are currently used to help physicians make decisions based on whether a patient should be put on statins, however its utility in informing prescribing decisions for blood pressure treatments was previously unknown.

In the current study, the Johns Hopkins researchers studied data collected from 3,733 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), in which a baseline blood pressure and coronary calcium score were measured for each. Using the Atherosclerotic Cardiovascular Disease Risk Algorithm, the study investigators also calculated each individual’s heart disease risk using traditional risk factors such as cholesterol levels and family history of disease.

Participants were followed up with on an annual basis, with 642 heart disease-related events – such as heart attack and stroke – occurring within a ten-year period. The study found that participants with a calcium score of zero and high calculated risk of heart disease, had a relatively low rate of actual heart disease-related events. In contrast, participants with a high calcium score but a low predicted risk of heart disease, had a higher actual event rate if their blood pressure was just under the cutoff of 140 millimeters of mercury.

“It may be that if patients are in that blood pressure treatment gray zone with a high risk score but their coronary artery calcium score is zero, then they don’t need to be treated aggressively to 120 millimeters of mercury and can be treated to 140 instead,” said McEvoy. “But if patients have a high calcium score and are in the gray zone, then it would make sense to go with 120 as a treatment goal.”

Because this study was observational in nature, the results will need to be confirmed in a clinical trial before being adopted in practice. In the US, about 70 million adults suffer from high blood pressure, which makes them more susceptible to heart attack, stroke and heart failure.

Keywords: Personalized Medicine, Hypertension, Cardiovascular Disease


Share this with your colleagues!

Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News

Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News

IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


How to Improve the Speed and Efficiency of Your Clinical Trials

High Performance Computing for High Content Screening - A Case Study

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Treatment of Psoriasis: Improvements Through Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.